Gregory Fiore
Founder at Exacis Biotherapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Matthew Angel | M | 43 |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | 4 years |
William Wexler | M | 65 | 2 years | |
James Pan | M | - |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | 4 years |
Mark Corrigan | M | 66 |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | 4 years |
Megan Yung | F | - | 1 years | |
Dorothy Clarke | F | 59 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Charles Cherington | M | 61 | 2 years | |
Dennis Langer | M | 73 | 1 years | |
Richard Wagner | M | 63 | - | |
Erin Enright | F | 63 | - | |
Nicholas Singer | M | 44 | 1 years | |
Erich Mohr | M | 70 | 1 years | |
Brant Binder | M | - | - | |
Heather Redman | F | 59 | - | |
Kevin D'Amour | M | 51 | 1 years | |
Andrew Jackson | M | 55 | 1 years | |
Roger Sidhu | M | 48 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 17 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gregory Fiore
- Personal Network